LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Listă Acțiuni・Fate Therapeutics Inc

Fate Therapeutics Inc

Închisă

SectorSănătate

2.55 -6.59

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

2.54

Maxim

2.73

Indicatori cheie
By Trading Economics
Venit	1.2M -31M
Vânzări	-70K 1.3M
EPS	-0.26
Marjă de profit	-2,402.848
Angajați	161
EBITDA	12M -30M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+74.45% upside

Dividende
By Dow Jones
Următoarele câștiguri	10 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	66M 319M
Deschiderea anterioară	9.14
Închiderea anterioară	2.55

Sentimentul știrilor

By Acuity

84%

16%

305 / 344 Clasament în Healthcare

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 iun. 2026, 20:30 UTC

Câștiguri

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 iun. 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 iun. 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 iun. 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 iun. 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 iun. 2026, 23:01 UTC

Achiziții, Fuziuni, Preluări

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 iun. 2026, 23:01 UTC

Achiziții, Fuziuni, Preluări

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 iun. 2026, 23:00 UTC

Achiziții, Fuziuni, Preluări

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 iun. 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 iun. 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 iun. 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 iun. 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 iun. 2026, 21:00 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 iun. 2026, 20:46 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:38 UTC

Câștiguri

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 iun. 2026, 20:21 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:12 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Product Rev $594M

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Loss $177M >PANW

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

74.45% sus

Prognoză pe 12 luni

Medie 4.78 USD 74.45%

Maxim 7 USD

Minim 2.2 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Fate Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

305 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.